Scientists and health officials are working 24/7 to provide an exit strategy to the coronavirus pandemic through the development of an effective vaccine. There is no known scientific cure for ...

In an exclusive interview, Sally Susman, a pioneer in corporate comms, recounts finding out that Pfizer's COVID-19 vaccine ...

Pfizer received FDA approval to enroll adolescents in its COVID-19 vaccine trial. Experts say it's an important step aimed at determining whether a vaccine could be safe and effective in children.

COVID-19 brought unprecedented public attention to the development, regulation, and timeline for products that prevent deadly infections, potentially heralding an era of vaccine innovation marked ...

Covid-19 vaccine stocks are back in focus, as cases in the U.S. surge with the spread of the highly infectious Delta variant of the virus. The seven-day average for Covid-19 cases stood at around ...

Development of new coronavirus vaccines may be hitting critical mass. Here’s how they work By Maggie Fox, CNN 8 minute read ...

Last month, the World Health Organization (WHO) estimated it would take 18 months to develop a vaccine for the novel coronavirus (COVID-19). Here is an update on the progress of several major ...

The coronavirus disease 2019 (COVID-19) vaccines that are leading the pack are utilizing a new vaccine technology that has never been approved for human use by the FDA. As a result, there are a ...

Many of the vaccines that are in development for COVID-19 were made possible because researchers had seed funding for technologies that make rapid vaccine development possible. That funding came from ...

As COVID-19 continues to spread across the U.S., impacting our daily lives and creating an uncertain future, the world eagerly awaits a vaccine – something that is likely 12 to 18 months away.

Some of the federal government’s top health officials are suggesting a vaccine for COVID-19 could be released in less than two months. The move would be made through a special emergency ...

Covid-19 vaccine stocks are back in focus, as cases in the U.S. surge with the spread of the highly infectious Delta variant of the virus. The seven-day average for Covid-19 cases stood at around ...